Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2014

01-03-2014 | NON-THEMATIC REVIEW

Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer

Authors: Suh Youn Ko, Gregory L. Blatch, Crispin R. Dass

Published in: Cancer and Metastasis Reviews | Issue 1/2014

Login to get access

Abstract

Despite advanced screening technology and cancer treatments available today, metastasis remains an ongoing major cause of cancer-related deaths worldwide. Typically, colorectal cancer is one of the cancers treatable by surgery in conjunction with chemotherapy when it is detected at an early stage. However, it still ranks as the second highest modality and mortality of cancer types in western countries, and this is mostly due to a recurrence of metastatic colorectal cancer post-resection of the primary malignancy. Colorectal cancer metastases predominantly occur in the liver and lung, and yet the molecular mechanisms that regulate these organ-specific colorectal cancer metastases are largely unknown. Therefore, the identification of any critical molecule, which triggers malignancy in colorectal cancer, would be an excellent target for treatment. Netrin-1 was initially discovered as a chemotropic neuronal guidance molecule, and has been marked as a regulator for many cancers including colorectal cancer. Here, we summarise key findings of the role of netrin-1 intrinsic to colorectal cancer cells, extrinsic to the tumour microenvironment and angiogenesis, and consequently, we evaluate netrin-1 as a potential target molecule for metastasis.
Literature
1.
Spano, D., Heck, C., De Antonellis, P., Christofori, G., & Zollo, M. (2012). Molecular networks that regulate cancer metastasis. Seminars in Cancer Biology, 22(3), 234–249.PubMed
2.
Mendoza, M., & Khanna, C. (2009). Revisiting the seed and soil in cancer metastasis. The International Journal of Biochemistry & Cell Biology, 41(7), 1452–1462.
3.
Brooks, S. A., Lomax-Browne, H. J., Carter, T. M., Kinch, C. E., & Hall, D. M. S. (2010). Molecular interactions in cancer cell metastasis. Acta Histochemica, 112(1), 3–25.PubMed
4.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews Cancer, 3(6), 453–458.PubMed
5.
Oppenheimer, S. B. (2006). Cellular basis of cancer metastasis: a review of fundamentals and new advances. Acta Histochemica, 108(5), 327–334.PubMed
6.
Eccles, S. A., & Welch, D. R. (2007). Metastasis: recent discoveries and novel treatment strategies. The Lancet, 369(9574), 1742–1757.
7.
Hart, I. R., & Fidler, I. J. (1981). The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 651(1), 37–50.
8.
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572.PubMed
9.
Langley, R. R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited—the role of tumor–stroma interactions in metastasis to different organs. International Journal of Cancer, 128(11), 2527–2535.
10.
Kawaguchi, T., & Nakamura, K. (1986). Analysis of the lodgement and extravasation of tumor cells in experimental models of hematogenous metastasis. Cancer Metastasis Reviews, 5(2), 77–94.PubMed
11.
Honn, K. V., Tang, D. G., Grossi, I., Duniec, Z. M., Timar, J., Renaud, C., et al. (1994). Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Research, 54(2), 565–574.PubMed
12.
Al-Mehdi, A. B., Tozawa, K., Fisher, A. B., Shientag, L., Lee, A., & Muschel, R. J. (2000). Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Medicine, 6(1), 100–102.PubMed
13.
Sierra, A. (2005). Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resistance Updates, 8(4), 247–257.PubMed
14.
Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3(6), 401–410.PubMed
15.
Dai, C. Y., Haqq, C. M., & Puzas, J. E. (2006). Molecular correlates of site-specific metastasis. Seminars in Radiation Oncology, 16(2), 102–110.PubMed
16.
Paget, S. (1889). The distribution of secondary growth in cancer of breast. The Lancet, 1, 571–573.
17.
Ewing, J. (1928). Neoplastic diseases: a treatise on tumors. Philadelphia: Saunders.
18.
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893–2917.
19.
Center, M. M., Jemal, A., & Ward, E. (2009). International trends in colorectal cancer incidence rates. Cancer Epidemiology, Biomarkers & Prevention, 18(6), 1688–1694.
20.
D'Angelica, M. (2013). Staging stage IV colorectal cancer. Annals of Surgical Oncology, 1–2.
21.
22.
Mehlen, P., & Guenebeaud, C. (2010). Netrin-1 and its dependence receptors as original targets for cancer therapy. Current Opinion in Oncology, 22(1), 46–54.PubMed
23.
Mehlen, P., & Thibert, C. (2004). Dependence receptors: between life and death. Cellular and Molecular Life Sciences, 61(15), 1854–1866.PubMed
24.
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 3(5), 391–400.PubMed
25.
Folkman, J. (1991). Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symposia, 22, 339.PubMed
26.
Gullino, P. M. (1978). Angiogenesis and oncogenesis. Journal of the National Cancer Institute, 61(3), 639.PubMed
27.
Harris, A. L. (2002). Hypoxia—a key regulatory factor in tumour growth. Nature Reviews Cancer, 2(1), 38–47.PubMed
28.
Weis, S. M., & Cheresh, D. A. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine, 17(11), 1359–1370.PubMed
29.
Vartanian, A. A. (2012). Signaling pathways in tumor vasculogenic mimicry. Biochemistry (Moscow), 77(9), 1044–1055.
30.
Rmali, K. A., Puntis, M. C. A., & Jiang, W. G. (2007). Tumour-associated angiogenesis in human colorectal cancer. Colorectal Disease: The Official Journal of The Association of Coloproctology of Great Britain and Ireland, 9(1), 3–14.
31.
Ellis, L. M., Takahashi, Y., Liu, W., & Shaheen, R. M. (2000). Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. The Oncologist, 5(suppl 1), 11–15.PubMed
32.
Tokunaga, T., Oshika, Y., Abe, Y., Ozeki, Y., Sadahiro, S., Kijima, H., et al. (1998). Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. British Journal Of Cancer, 77(6), 998–1002.PubMedCentralPubMed
33.
Vaish, V., & Sanyal, S. N. (2012). Role of sulindac and celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. Biomedicine & Pharmacotherapy, 66(5), 354–367.
34.
Fukuda, R., Kelly, B., & Semenza, G. L. (2003). Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Research, 63(9), 2330–2334.PubMed
35.
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93(5), 705–716.PubMed
36.
Taketo, M. M. (2012). Roles of stromal microenvironment in colon cancer progression. Journal of Biochemistry, 151(5), 477–481.PubMed
37.
Yoshida, S., Amano, H., Hayashi, I., Kitasato, H., Kamata, M., Inukai, M., et al. (2003). COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Laboratory Investigation, 83(10), 1385–1394.PubMed
38.
Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., & Semenza, G. L. (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP Kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry, 277(41), 38205–38211.PubMed
39.
Subbaramaiah, K., & Dannenberg, A. J. (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends in Pharmacological Sciences, 24(2), 96–102.PubMed
40.
McGettigan, P. (2006). Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 296(13), 1633–1644.PubMed
41.
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New England Journal of Medicine, 360(6), 563–572.PubMed
42.
43.
Guijarro-Muñoz, I., Sánchez, A., Martínez-Martínez, E., García, J., Salas, C., Provencio, M., et al. (2013). Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Medical Oncology, 30(2), 1–8.
44.
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a glance. Journal of Cell Science, 125(23), 5591–5596.PubMed
45.
Huszar, M., Itzhaki, O., Leibovici, J., & Sinai, J. (2011). The tumor microenvironment: part 1. Immunotherapy, 3(11), 1367–1384.PubMed
46.
Bissell, M. J., Kenny, P. A., & Radisky, D. C. (2005). Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harbor Symposia on Quantitative Biology, 70, 343–356.PubMedCentralPubMed
47.
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. The Journal of Cell Biology, 137(1), 231–245.PubMedCentralPubMed
48.
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–32.PubMed
49.
50.
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.PubMedCentralPubMed
51.
Rustgi, A. K. (2007). The genetics of hereditary colon cancer. Genes and Development, 21(20), 2525–2538.PubMed
52.
Fearon, E., Cho, K., Nigro, J., Kern, S., Simons, J., Ruppert, J., et al. (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. Science, 247(4938), 49–56.PubMed
53.
Kitamura, T., Kometani, K., Hashida, H., Matsunaga, A., Miyoshi, H., Hosogi, H., et al. (2007). SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nature Genetics, 39(4), 467–475.PubMed
54.
Taketo, M. M. (2009). Role of bone marrow-derived cells in colon cancer: lessons from mouse model studies. Journal of Gastroenterology, 44(2), 93–102.PubMed
55.
Kitamura, T., Fujishita, T., Loetscher, P., Revesz, L., Hashida, H., Kizaka-Kondoh, S., et al. (2010). Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proceedings of the National Academy of Sciences, 107(29), 13063–13068.
56.
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (New York, N.Y.), 295(5564), 2387–2392.
57.
Overall, C. M., & Kleifeld, O. (2006). Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer, 6(3), 227–239.PubMed
58.
Peterson, J. T. (2006). The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular Research, 69(3), 677–687.PubMed
59.
Murphy, G., & Nagase, H. (2008). Progress in matrix metalloproteinase research. Molecular Aspects of Medicine, 29(5), 290–308.PubMedCentralPubMed
60.
Masahiro, S., Masahiro, A., Haruhiko, F., Koji, A., Hisahiro, H., Yoshiharu, S., et al. (2011). Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell, 19, 125–137.
61.
Kennedy, T. E., Serafini, T., de la Torre, J., & Tessier-Lavigne, M. (1994). Netrins are diffusible chemotropic factors for commissural axons in the embryonic spinal cord. Cell, 78(3), 425–435.PubMed
62.
Mehlen, P., & Furne, C. (2005). Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cellular and Molecular Life Sciences, 62(22), 2599–2616.PubMed
63.
Bradford, D., Cole, S. J., & Cooper, H. M. (2009). Netrin-1: diversity in development. The International Journal of Biochemistry & Cell Biology, 41(3), 487–493.
64.
Serafini, T., Kennedy, T. E., Gaiko, M. J., Mirzayan, C., Jessell, T. M., & Tessier-Lavigne, M. (1994). The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6. Cell, 78(3), 409–424.PubMed
65.
Barallobre, M. J., Pascual, M., Del Río, J. A., & Soriano, E. (2005). The Netrin family of guidance factors: emphasis on Netrin-1 signalling. Brain Research Reviews, 49(1), 22–47.PubMed
66.
Sun, K. L. W., Correia, J. P., & Kennedy, T. E. (2011). Netrins: versatile extracellular cues with diverse functions. Development, 138(11), 2153–2169.
67.
68.
Ko, S. Y., Dass, C. R., & Nurgali, K. (2012). Netrin-1 in the developing enteric nervous system and colorectal cancer. Trends in Molecular Medicine, 18(9), 544–554.PubMed
69.
Serafini, T., Colamarino, S. A., Leonardo, E. D., Wang, H., Beddington, R., Skarnes, W. C., et al. (1996). Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell, 87(6), 1001–1014.PubMed
70.
Hong, K., Hinck, L., Nishiyama, M., Poo, M.-m., Tessier-Lavigne, M., & Stein, E. (1999). A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell, 97(7), 927–941.PubMed
71.
Alcantara, S., Ruiz, M., De Castro, F., Soriano, E., & Sotelo, C. (2000). Netrin 1 acts as an attractive or as a repulsive cue for distinct migrating neurons during the development of the cerebellar system. Development, 127(7), 1359–1372.PubMed
72.
Yee, K. T., Simon, H. H., Tessier-Lavigne, M., & O'Leary, D. D. M. (1999). Extension of long leading processes and neuronal migration in the mammalian brain directed by the chemoattractant netrin-1. Neuron, 24(3), 607–622.PubMed
73.
Colamarino, S. A., & Tessier-Lavigne, M. (1995). The axonal chemoattractant netrin-1 is also a chemorepellent for trochlear motor axons. Cell, 81(4), 621–629.PubMed
74.
Baker, K. A., Moore, S. W., Jarjour, A. A., & Kennedy, T. E. (2006). When a diffusible axon guidance cue stops diffusing: roles for netrins in adhesion and morphogenesis. Current Opinion in Neurobiology, 16(5), 529–534.PubMed
75.
Kennedy, T. E., Wang, H., Marshall, W., & Tessier-Lavigne, M. (2006). Axon guidance by diffusible chemoattractants: a gradient of netrin protein in the developing spinal cord. The Journal of Neuroscience, 26(34), 8866–8874.PubMed
76.
Wit, J., & Verhaagen, J. (2007). Proteoglycans as modulators of axon guidance cue function. Semaphorins: receptor and intracellular signaling mechanisms. In R. J. Pasterkamp (Ed.), Advances in experimental medicine and biology (Vol. 600) (pp. 73–89). New York: Springer.
77.
Matsumoto, Y. (2007). Netrin-1/DCC signaling in commissural axon guidance requires cell-autonomous expression of heparan sulfate. The Journal of Neuroscience, 27(16), 4342.PubMed
78.
Cirulli, V., & Yebra, M. (2007). Netrins: beyond the brain. Nature Reviews Molecular Cell Biology, 8(4), 296–306.PubMed
79.
Wang, W., Brian Reeves, W., & Ramesh, G. (2008). Netrin-1 and kidney injury. I. Netrin-1 protects against ischemia-reperfusion injury of the kidney. American Journal of Physiology - Renal Physiology, 294(4), F739–F747.PubMedCentralPubMed
80.
Liu, Y., Stein, E., Oliver, T., Li, Y., Brunken, W. J., Koch, M., et al. (2004). Novel role for netrins in regulating epithelial behavior during lung branching morphogenesis. Current Biology, 14(10), 897–905.PubMedCentralPubMed
81.
Eichmann, A., Makinen, T., & Alitalo, K. (2005). Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes and Development, 19(9), 1013–1021.PubMed
82.
Mehlen, P., & Bredesen, D. E. (2004). The dependence receptor hypothesis. Apoptosis, 9(1), 37–49.PubMed
83.
Mehlen, P., & Llambi, F. (2005). Role of netrin-1 and netrin-1 dependence receptors in colorectal cancers. British Journal of Cancer, 93(1), 1–6.PubMedCentralPubMed
84.
Mazelin, L., Bernet, A., Bonod-Bidaud, C., Pays, L., Arnaud, S., Gespach, C., et al. (2004). Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature, 431(7004), 80–84.PubMed
85.
Dumartin, L., Quemener, C., Laklai, H., Herbert, J., Bicknell, R., Bousquet, C., et al. (2010). Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology, 138(4), 1595–1606.PubMed
86.
Delloye-Bourgeois, C., Brambilla, E., Coissieux, M.-M., Guenebeaud, C., Pedeux, R., Firlej, V., et al. (2009). Interference with netrin-1 and tumor cell death in non-small cell lung cancer. Journal of the National Cancer Institute, 101(4), 237–247.PubMed
87.
Fitamant, J., Guenebeaud, C., Coissieux, M.-M., Guix, C., Treilleux, I., Scoazec, J.-Y., et al. (2008). Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proceedings of the National Academy of Sciences, 105(12), 4850–4855.
88.
Castets, M., Broutier, L., Molin, Y., Brevet, M., Chazot, G., Gadot, N., et al. (2012). DCC constrains tumour progression via its dependence receptor activity. Nature, 482(7386), 534–537.
89.
Paradisi, A. (2010). Netrin-1, a missing link between chronic inflammation and tumor progression. Cell Cycle, 9(7), 1253.PubMed
90.
Paradisi, A., Maisse, C., Coissieux, M.-M., Gadot, N., Lépinasse, F., Delloye-Bourgeois, C., et al. (2009). Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proceedings of the National Academy of Sciences, 106(40), 17146–17151.
91.
Carmeliet, P., & Tessier-Lavigne, M. (2005). Common mechanisms of nerve and blood vessel wiring. Nature, 436(7048), 193–200.PubMed
92.
Lu, X., le Noble, F., Yuan, L., Jiang, Q., de Lafarge, B., Sugiyama, D., et al. (2004). The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature, 432(7014), 179–186.PubMed
93.
Park, K. W., Crouse, D., Lee, M., Karnik, S. K., Sorensen, L. K., Murphy, K. J., et al. (2004). The axonal attractant Netrin-1 is an angiogenic factor. Proceedings of the National Academy of Sciences of the United States of America, 101(46), 16210–16215.PubMedCentralPubMed
94.
Larrivée, B., Freitas, C., Trombe, M., Lv, X., DeLafarge, B., Yuan, L., et al. (2007). Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes and Development, 21(19), 2433–2447.PubMedCentralPubMed
95.
Dakouane-Giudicelli, M., Alfaidy, N., Bayle, P., Tassin de Nonneville, A., Studer, V., Rozenberg, P., et al. (2011). Hypoxia-inducible factor 1 controls the expression of the uncoordinated-5-B receptor, but not of netrin-1, in first trimester human placenta. The International Journal Of Developmental Biology, 55(10–12), 981–987.PubMed
96.
Wilson, B. D., Ii, M., Park, K. W., Suli, A., Sorensen, L. K., Larrieu-Lahargue, F., et al. (2006). Netrins promote developmental and therapeutic angiogenesis. Science, 313(5787), 640–644.PubMedCentralPubMed
97.
Castets, M., Coissieux, M.-M., Delloye-Bourgeois, C., Bernard, L., Delcros, J.-G., Bernet, A., et al. (2009). Inhibition of endothelial cell apoptosis by netrin-1 during angiogenesis. Developmental Cell, 16(4), 614–620.PubMed
98.
Lu, H., Wang, Y., He, X., Yuan, F., Lin, X., Xie, B., et al. (2012). Netrin-1 hyperexpression in mouse brain promotes angiogenesis and long-term neurological recovery after transient focal ischemia. Stroke, 43(3), 838–843.PubMed
99.
Li, Q., Yao, D., Ma, J., Zhu, J., Xu, X., Ren, Y., et al. (2011). Transplantation of MSCs in combination with netrin-1 improves neoangiogenesis in a rat model of hind limb ischemia. Journal of Surgical Research, 166(1), 162–169.PubMed
100.
Tsuchiya, A., Hayashi, T., Deguchi, K., Sehara, Y., Yamashita, T., Zhang, H., et al. (2007). Expression of netrin-1 and its receptors DCC and neogenin in rat brain after ischemia. Brain Research, 1159, 1–7.PubMed
101.
Shimizu, A., Nakayama, H., Wang, P., König, C., Akino, T., Sandlund, J., et al. (2013). Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein. Journal of Biological Chemistry, 288(4), 2210–2222.PubMedCentralPubMed
102.
Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer, 3(5), 362–374.PubMed
103.
Friedl, P., & Bröcker, E. B. (2000). The biology of cell locomotion within three-dimensional extracellular matrix. Cellular and Molecular Life Sciences CMLS, 57(1), 41–64.PubMed
104.
Rodrigues, S., De Wever, O., Bruyneel, E., Rooney, R. J., & Gespach, C. (2007). Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene, 26(38), 5615–5625.PubMed
105.
Nguyen, Q.-D., De Wever, O., Bruyneel, E., Hendrix, A., Xie, W.-Z., Lombet, A., et al. (2005). Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene, 24(56), 8240–8251.PubMed
106.
Forcet, C., Ye, X., Granger, L., Corset, V., Shin, H., Bredesen, D. E., et al. (2001). The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proceedings of the National Academy of Sciences, 98(6), 3416–3421.
107.
Arakawa, H. (2004). Netrin-1 and its receptors in tumorigenesis. Nature Review Cancer, 4(12), 978–987.
108.
Paradisi, A., Maisse, C., Bernet, A., Coissieux, M. M., Maccarrone, M., Scoazec, J. Y., et al. (2008). NF-κB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology, 135(4), 1248–1257.PubMed
109.
Yang, Y., Wang, X., Moore, D. R., Lightfoot, S. A., & Huycke, M. M. (2012). TNF-α mediates macrophage-induced bystander effects through Netrin-1. Cancer Research, 72(20), 5219–5229.PubMedCentralPubMed
110.
Ramesh, G., Berg, A., & Jayakumar, C. (2011). Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers, 16(2), 172–180.PubMedCentralPubMed
111.
Son, T. W., Yun, S. P., Yong, M. S., Seo, B. N., Ryu, J. M., Youn, H. Y., et al. (2013). Netrin-1 protects hypoxia-induced mitochondrial apoptosis through HSP27 expression via DCC- and integrin α6β4-dependent Akt, GSK-3β, and HSF-1 in mesenchymal stem cells. Cell Death and Disease, 4, e563. doi:10.​1038/​cddis.​2013.​94.PubMedCentralPubMed
112.
Uccelli, A., Moretta, L., & Pistoia, V. (2008). Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 8(9), 726–736.PubMed
113.
Pandey, P., Farber, R., Nakazawa, A., Kumar, S., Bharti, A., Nalin, C., et al. (2000). Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene, 19(16), 1975–1981.PubMed
114.
Dorsam, R. T., & Gutkind, J. S. (2007). G-protein-coupled receptors and cancer. Nature Reviews Cancer, 7(2), 79–94.PubMed
115.
George Paul, A., Sharma-Walia, N., Kerur, N., White, C., & Chandran, B. (2010). Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen. Cancer Research, 70(9), 3697–3708.PubMed
116.
Xie, H., Zou, L., Zhu, J., & Yang, Y. (2011). Effects of netrin-1 and netrin-1 knockdown on human umbilical vein endothelial cells and angiogenesis of rat placenta. Placenta, 32(8), 546–553.PubMed
117.
Wang, Q. H., Zhu, J. W., Zou, L., & Yang, Y. (2011). Role of axonal guidance factor netrin-1 in human placental vascular growth. Journal of Huazhong University of Science and Technology-Medical Sciences, 31(2), 246–250.
118.
Bouvrée, K., Larrivée, B., Lv, X., Yuan, L., DeLafarge, B., Freitas, C., et al. (2008). Netrin-1 inhibits sprouting angiogenesis in developing avian embryos. Developmental Biology, 318(1), 172–183.PubMed
Metadata
Title
Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer
Authors
Suh Youn Ko
Gregory L. Blatch
Crispin R. Dass
Publication date
01-03-2014
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9459-z

Other articles of this Issue 1/2014

Cancer and Metastasis Reviews 1/2014 Go to the issue

Clinical

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

EditorialNotes

Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges

NON-THEMATIC REVIEW

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine

Clinical

Concomitant resistance and early-breast cancer: should we change treatment strategies?

NON-THEMATIC REVIEW

Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation

OriginalPaper

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits